PDF(Pubmed)
Abstract：
UNASSIGNED: The COVID-19 pandemic has introduced new challenges to the diagnosis and management of pediatric inflammatory bowel disease (IBD). Many patients have had only limited access to their providers through telemedicine, and many chose to delay nonemergent treatment.
UNASSIGNED: A retrospective chart review of patients with IBD seen by the Pediatric Gastroenterology Division at Doernbecher Children\'s Hospital from January 2018 to August 2021 was conducted. The study cohort was divided into 2 groups: those presenting before the onset of the COVID-19 pandemic (January 1, 2018 to February 28, 2020) and those presenting during the pandemic (March 1, 2020 to August 1, 2021). Variables collected included: age, sex, race, ethnicity, IBD type, insurance type, location of residence. Primary outcome measures selected focused on disease severity, initial type of treatment, or surgical intervention offered. A subgroup analysis of the new diagnosis patients was performed. Data were analyzed using independent t-tests, chi-squared analysis, and Wilcoxon rank sum tests.
UNASSIGNED: Two hundred and eleven patients met inclusion criteria, 107 (72 new diagnoses, 35 admissions) within the pre-COVID epoch and 104 (67 new diagnoses, 37 admissions) within the during-COVID epoch. Patients in the during-COVID epoch had higher fecal calprotectin level and were more likely to be started on a biologic as initial treatment. Patients admitted during COVID for IBD flare were more likely to require surgical intervention. Subgroup analysis of newly diagnosed patients revealed higher incidence of comorbid depression and anxiety.
UNASSIGNED: Our review identified increased disease severity in newly diagnosed pediatric patients with IBD as well as pediatric patients admitted for flare during COVID. Increases in anxiety and depression rates during COVID may have contributed to worsened disease severity.
UNASSIGNED: A retrospective chart review of patients with IBD seen by the Pediatric Gastroenterology Division at Doernbecher Children\'s Hospital from January 2018 to August 2021 was conducted. The study cohort was divided into 2 groups: those presenting before the onset of the COVID-19 pandemic (January 1, 2018 to February 28, 2020) and those presenting during the pandemic (March 1, 2020 to August 1, 2021). Variables collected included: age, sex, race, ethnicity, IBD type, insurance type, location of residence. Primary outcome measures selected focused on disease severity, initial type of treatment, or surgical intervention offered. A subgroup analysis of the new diagnosis patients was performed. Data were analyzed using independent t-tests, chi-squared analysis, and Wilcoxon rank sum tests.
UNASSIGNED: Two hundred and eleven patients met inclusion criteria, 107 (72 new diagnoses, 35 admissions) within the pre-COVID epoch and 104 (67 new diagnoses, 37 admissions) within the during-COVID epoch. Patients in the during-COVID epoch had higher fecal calprotectin level and were more likely to be started on a biologic as initial treatment. Patients admitted during COVID for IBD flare were more likely to require surgical intervention. Subgroup analysis of newly diagnosed patients revealed higher incidence of comorbid depression and anxiety.
UNASSIGNED: Our review identified increased disease severity in newly diagnosed pediatric patients with IBD as well as pediatric patients admitted for flare during COVID. Increases in anxiety and depression rates during COVID may have contributed to worsened disease severity.
摘要：
■COVID-19大流行给小儿炎症性肠病（IBD）的诊断和管理带来了新的挑战。许多患者通过远程医疗只能有限地接触他们的提供者，许多人选择推迟非紧急治疗。
对2018年1月至2021年8月Doernbecher儿童医院小儿胃肠病科就诊的IBD患者进行回顾性图表回顾。研究队列分为两组：在COVID-19大流行爆发前(2018年1月1日至2020年2月28日)出现的人群和在大流行期间(2020年3月1日至2021年8月1日)出现的人群。收集的变量包括：年龄，性别,种族,种族,IBD类型,保险类型,居住地。选择的主要结局指标侧重于疾病严重程度，初始类型的治疗，或提供手术干预。对新诊断患者进行了亚组分析。数据采用独立t检验进行分析，卡方分析，和Wilcoxon等级和检验.
■二百一十一名患者符合纳入标准，107（72例新诊断，35例入院)在COVID前期和104例(67例新诊断，37次入院)在COVID时期内。COVID期间的患者粪便钙卫蛋白水平较高，更有可能开始接受生物制剂作为初始治疗。COVID期间因IBD发作而入院的患者更有可能需要手术干预。新诊断患者的亚组分析显示，抑郁和焦虑共病的发生率更高。
■我们的审查发现，新诊断的IBD儿科患者以及COVID期间因耀斑入院的儿科患者的疾病严重程度增加。COVID期间焦虑和抑郁率的增加可能导致疾病严重程度恶化。
对2018年1月至2021年8月Doernbecher儿童医院小儿胃肠病科就诊的IBD患者进行回顾性图表回顾。研究队列分为两组：在COVID-19大流行爆发前(2018年1月1日至2020年2月28日)出现的人群和在大流行期间(2020年3月1日至2021年8月1日)出现的人群。收集的变量包括：年龄，性别,种族,种族,IBD类型,保险类型,居住地。选择的主要结局指标侧重于疾病严重程度，初始类型的治疗，或提供手术干预。对新诊断患者进行了亚组分析。数据采用独立t检验进行分析，卡方分析，和Wilcoxon等级和检验.
■二百一十一名患者符合纳入标准，107（72例新诊断，35例入院)在COVID前期和104例(67例新诊断，37次入院)在COVID时期内。COVID期间的患者粪便钙卫蛋白水平较高，更有可能开始接受生物制剂作为初始治疗。COVID期间因IBD发作而入院的患者更有可能需要手术干预。新诊断患者的亚组分析显示，抑郁和焦虑共病的发生率更高。
■我们的审查发现，新诊断的IBD儿科患者以及COVID期间因耀斑入院的儿科患者的疾病严重程度增加。COVID期间焦虑和抑郁率的增加可能导致疾病严重程度恶化。
